Georges El Hachem

Georges El Hachem

Auto-generated profile, based on publicly available information

Georges El Hachem

Jules Bordet Institute, Université Libre de Bruxelles, Brussels, 1000, Belgium

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
GHGeorges El Hachem
Georges El Hachem
AGAndrea Gombos
Andrea Gombos
AAAhmad Awada
Ahmad Awada
Breast cancer is a global health issue. For decades, breast cancer was classified into many histological subtypes on the basis of microscopic and immunohistochemical evaluation. The discovery of many key genomic driver events involved in breast cancer carcinogenesis resulted in a better understanding of the tumor biology, the disease heterogeneity and the prognosis leading to the discovery of new modalities of targeted therapies and opening horizons toward a more personalized medicine. In recent years, many therapeutic options emerged in the field of metastatic breast carcinoma, especially for the luminal subtypes. They were able to transform the course of the disease while maintaining quality of life. However, the options are still limited for triple-negative breast cancer, but the better knowledge of its complex biology and the discovery of molecular targets are promising for more efficient novel therapies.

28 October 2014 in F1000Research
Verified
Journal Article
Open access
PDF file
MAMounia Amzerin
Mounia Amzerin
CGCamilo Garcia
Camilo Garcia
CSClaudia Stanciu
Claudia Stanciu
IVIsabelle Veys
Isabelle Veys
AAAhmad Awada
Ahmad Awada
AGAndrea Gombos
Andrea Gombos
In this paper we report two interesting cases of metastatic ovarian cancer. The first case is a patient who developed rectal and breast metastases mimicking an inflammatory breast cancer. In the second case, subclinical breast and axillary lymph node metastases were revealed by PET/CT. Metastases in the breast originating from solid tumors are extremely rare. The ovarian primitive is the fourth most common origin. The occurrence of breast metastasis is associated with an advanced disease and a poor prognosis. Their incidence is increasing since they are found more often due to better imaging techniques and to better treatment that, accordingly, improve patients’ survival. Thus, unusual sites of metastases are more and more reported. Indeed, some authors reported the occurrence of colorectal metastases from ovarian cancer. However, they remain much less frequent.

9 December 2014 in F1000Research
Verified
Journal Article
Open access
PDF file
MAMounia Amzerin
Mounia Amzerin
CGCamilo Garcia
Camilo Garcia
CSClaudia Stanciu
Claudia Stanciu
IVIsabelle Veys
Isabelle Veys
AAAhmad Awada
Ahmad Awada
AGAndrea Gombos
Andrea Gombos
In this paper we report two interesting cases of metastatic ovarian cancer. The first case is a patient who developed rectal and breast metastases mimicking an inflammatory breast cancer. In the second case, subclinical breast and axillary lymph node metastases were revealed by PET/CT. Metastases in the breast originating from solid tumors are extremely rare. The ovarian primitive is the fourth most common origin. The occurrence of breast metastasis is associated with an advanced disease and a poor prognosis. Their incidence is increasing since they are found more often due to better imaging techniques and to better treatment that, accordingly, improve patients’ survival. Thus, unusual sites of metastases are more and more reported. Indeed, some authors reported the occurrence of colorectal metastases from ovarian cancer. However, they remain much less frequent.

17 February 2022 in Annales de Dermatologie et de Vénéréologie
Verified
Journal Article
Closed access
BSBoutros Soutou
Boutros Soutou
GHG. El Hachem
G. El Hachem
JHJ. Helou
J. Helou
FSF. Stéphan
F. Stéphan
EKE. Kechichian
E. Kechichian
RTR. Tomb
R. Tomb

15 November 2024 in Future Oncology
Verified
Journal Article
Closed access
ATArafat Tfayli
Arafat Tfayli
HGHady Ghanem
Hady Ghanem
FNFadi Nasr
Fadi Nasr
HKHampig Raphael Kourie
Hampig Raphael Kourie
GHGeorges El Hachem
Georges El Hachem
JKJoseph Kattan
Joseph Kattan
Treatment of non-small-cell lung cancers (NSCLC) has evolved over the last decade. According to studies, the use of targeted therapies has significantly increased the life expectancy of patients. Moreover, ALK-tyrosine kinase inhibitors (ALK-TKIs) have improved clinical outcomes. In Lebanon, translating recommendations into clinical practice remains challenging. A Lebanese expert panel of oncologists was convened to describe the management paradigm and the clinical evidence supporting the optimal use of next-generation TKIs in patients with ALK-rearranged NSCLC and to provide an expert overview of local challenges and recommendations for optimizing the management of advanced NSCLC in Lebanese patients. The experts agreed that these recommendations should be part of a healthcare strategy to be implemented at the national level.